



Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting

May 15, 2013

-- Exelixis to host investor briefing via live webcast on Sunday, June 2, 2013

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 15, 2013-- Exelixis, Inc. (NASDAQ:EXEL) reiterated its slate of activities in conjunction with the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2013, in Chicago, Illinois. Clinical data from cabozantinib will be the subject of nine separate data presentations, including one oral presentation, one poster discussion, and seven general poster presentations. The company will also host an investor briefing that will be webcast live on Sunday, June 2, 2013. This year's ASCO Annual Meeting will be the first in which investigators present overall survival data for castration-resistant prostate cancer patients treated with cabozantinib as part of the phase 2, non-randomized expansion cohort.

The full roster of cabozantinib data presentations expected at the meeting (all times Central Daylight Time):

Oral Presentation

- Abstract 6000: "Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study."

Dr. Steven I. Sherman, The University of Texas MD Anderson Cancer Center, Houston, TX

Oral Abstract Session: Head/Neck Cancer

Sunday, June 2, 8:00-8:15 a.m., Room E354a

Poster Discussion Presentations

- Abstract 5026: "An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort."

Dr. Howard I. Scher, Memorial Sloan-Kettering Cancer Center, New York, NY

Poster Discussion Session: Genitourinary (Prostate) Cancer

Saturday, June 1, 8:00 a.m. – noon (poster display, Room E450a); 12:00 – 1:00 p.m. (discussion, E Arie Crown Theater)

General Poster Presentations

- Abstract 6090: "Long-term disease control of ≥ 2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study."

Dr. Ezra Cohen, The University of Chicago Medicine, Chicago, IL

General Poster Session: Head/Neck Cancer

Saturday, June 1, 8:00-11:45 a.m., S Hall A2

- Abstract 9094: "Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT)."

Dr. Adil Daud, UCSF, San Francisco, CA

General Poster Session: Melanoma/Skin Cancers

Saturday, June 1, 8:00-11:45 a.m., S Hall A2

- Abstract 5073: "Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib."

Dr. Josef J. Fox, Memorial Sloan-Kettering Cancer Center, New York, NY

General Poster Session: Genitourinary (Prostate) Cancer

Monday, June 3, 8:00-11:45 a.m., S Hall A2

- Abstract TPS5094: "A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219)." [Note: This is an Investigator-Sponsored Trial.]

Dr. Petros Grivas, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
General Poster Session: Genitourinary Cancers (Trials in Progress subsession)
Monday, June 3, 8:00-11:45 a.m., S Hall A2

- Abstract TPS4589: "A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma." [Note: This is a study conducted by the National Cancer Institute's Cancer Therapy Evaluation Program (NCI-CTEP).]

Dr. Andrea Apolo, Center for Cancer Research, National Cancer Institute, Bethesda, MD
General Poster Session: Genitourinary (Nonprostate) Cancer (Trials in Progress subsession)
Monday, June 3, 8:00-11:45 a.m., S Hall A2

- Abstract TPS5095: "A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC)." [Note: This is an NCI-CTEP study.]

Dr. Fatima Karzai, Center for Cancer Research, National Cancer Institute, Bethesda, MD
General Poster Session: Genitourinary (Prostate) Cancer (Trials in Progress subsession)
Monday, June 3, 8:00-11:45 a.m., S Hall A2

- Abstract 4543: "Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC)." [Note: These are NCI-CTEP studies.]

Dr. Andrea Apolo, Center for Cancer Research, National Cancer Institute, Bethesda, MD
General Poster Session: Genitourinary (Nonprostate) Cancer
Monday, June 3, 8:00-11:45 a.m., S Hall A2

Details on May 15th Release of 2013 ASCO Annual Meeting Abstracts

The 2013 ASCO Annual Meeting abstracts featuring cabozantinib will be posted publicly on www.asco.org today, Wednesday, May 15, 2013, at 6:00 p.m. EDT. The complete and current data relating to the abstracts will be delivered during the investigators' presentations at the meeting itself, at the dates and times listed above.

Investor Briefing at the 2013 ASCO Annual Meeting

Exelixis will hold an investor briefing that will be webcast live on Sunday, June 2, 2013, starting at 6:00 p.m. CDT. During the briefing, Exelixis management and other presenters will review and provide context for the latest clinical data for cabozantinib presented at the 2013 ASCO Annual Meeting. The webcast will be accessible via the Event Calendar page under Investors & Media at www.exelixis.com.

An archived replay of the webcast will be available on the Event Calendar page under Investors & Media at www.exelixis.com and audio-only via phone until 11:59 p.m. EDT/8:59 p.m. PDT on July 2, 2013. Access numbers for the audio-only phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 43782784.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ™ (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.

Source: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, (650) 837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com